Investorideas.com

Get investor ideas from our AI, cannabis, cleantech, crypto, gaming, mining, sports podcasts - be a guest or sponsor: call 800 665 0411

 


BiotechIndustryStocks.com - A Leading Global Investor Website for Biotech Industry Stocks

BiotechIndustryStocks.com - investing ideas in biotechnology stocks, medical technology, telemedicine, Covid-19

Like Biotech Stocks? View our Biotech Stocks Directory    Get News Alerts on Biotech Stocks


Featured Biotech stocks - Feature Your Company & Product Here

Biotech News

Analyst: Biotech Expecting a 'Catalyst-Rich' Second Half of the Year
May 14, 2021 (Investorideas.com Newswire) An H.C. Wainwright & Co. report discusses Gritstone Bio's recent earnings and significant corporate events as the firm plans to release data on cancer and COVID-19 vaccines later this year.

Multiplan Shares Rise on Strong YoY Gain in Q1 Net Income and Forward Outlook
May 14, 2021 (Investorideas.com Newswire) Multiplan Corp. shares traded 17% higher after the company reported Q1/21 net income of $45.9 million, compared to a net loss of $2.6 million in the corresponding quarter last year.

Life Sciences Firm Is at 'an Inflection Point with Significant Sales Increases Just around the Corner'
May 13, 2021 (Investorideas.com Newswire) Noble Capital Markets noted in a research report that shortly after receiving its largest single order to date, a 4.4-ton order for OxC-beta Livestock, Avivagen Inc. has received a new order for 4 tons per month from its representative in Mexico.

Biotech Stock News: Annovis Bio (NYSE American: ANVS) Files for FDA Orphan Drug Designation for ANVS401 for the Treatment of Alzheimer's Disease in Persons with Down Syndrome
Berwyn, Pennsylvania - May 13, 2021 (Newsfile Corp.) (Investorideas.com Newswire) Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, today announced it has filed an application with the U.S. Food and Drug Administration (FDA) to receive orphan drug designation for its lead drug candidate, ANVS401, for the treatment of AD in persons with Down syndrome (DS), referred to as DS-AD.

HEALTHMED SERVICES LTD (OTC: $HEME) Announces Appointment of New Director to its Board, @healthmedserv
May 11, 2021 (Investorideas.com Newswire) HEALTHMED SERVICES LTD, Palm Desert, California is quoted on the OTCmarkets under the ticker symbol "HEME"

Twist Bioscience Shares Wind Higher After Firm Posts 62% YoY Increase in Q2 Revenue
May 10, 2021 (Investorideas.com Newswire) Shares of Twist Bioscience Corp. traded 14% higher after the firm reported that orders in Q2/21 grew by 69% year-over-year and that it is raising its FY/21 revenue guidance to $121–129 million.

Telemedicine to Save Healthcare Industry $21 Billion Globally by 2025; Driven by Teleconsultation Services
>Hampshire, UK - May 10, 2021 (Investorideas.com Newswire) A new study by Juniper Research has found that telemedicine will save the healthcare industry $21 billion in costs by 2025; rising from $11 billion in 2021.

Biotech Stock News: Defence Therapeutics (CSE: DTC), Strong Therapeutics Pipeline: ADC's, Cancer and COVID Vaccines
Vancouver, British Columbia - May 7, 2021 (Newsfile Corp.) (Investorideas.com Newswire) Defence Therapeutics Inc. (CSE: DTC) ("Defence" or the "Company"), a Canadian biotech Company focused on the development of novel and highly specific vaccines and antibody-drug conjugates targeting cancer and infectious diseases, is pleased to begin its trading on the CSE as of today.

Biotech's Gene Therapy Assets Put It 'Ahead of the Pack'
May 6, 2021 (Investorideas.com Newswire) Sio Gene Therapies' focus and strategic portfolio are discussed in an H.C. Wainwright & Co. coverage initiation report.

CryoLife Shares Trade 18% Higher on Q1 Financial Results
May 3, 2021 (Investorideas.com Newswire) Shares of CryoLife Inc. set a new 52-week high intraday price after the company reported that total revenues in Q1/21 increased by 7% YoY to $71.1 million.

Subscribe to Biotech News RSS

Submit Articles   Search More Articles

Biotech Stock ETF's

First Trust NYSE Arca Biotech ETF ( NYSEArca: FBT ) The investment seeks investment results that correspond generally to the price and yield (before the fund's fees and expenses) of an equity index called the NYSE Arca Biotechnology Index(SM). The fund will normally invest at least 90% of its net assets plus the amount of any borrowings for investment purposes in common stocks that comprise the index. The index is an equal-dollar weighted index designed to measure the performance of a cross section of companies in the biotechnology industry that are primarily involved in the use of biological processes to develop products or provide services. The fund is non-diversified.

iShares US Healthcare ( NYSEArca: IYH ) The investment seeks to track the investment results of an index composed of U.S. equities in the healthcare sector. The fund generally invests at least 90% of its assets in securities of the underlying index and in depositary receipts representing securities of the underlying index. It seeks to track the investment results of the Dow Jones U.S. Health Care Index (the "underlying index"), which measures the performance of the healthcare sector of the U.S. equity market. The fund is non-diversified.

iShares US Healthcare Providers ( NYSEArca: IHF ) The investment seeks to track the investment results of an index composed of U.S. equities in the healthcare providers sector. The fund generally invests at least 90% of its assets in securities of the underlying index and in depositary receipts representing securities of the underlying index. It seeks to track the investment results of the Dow Jones U.S. Select Health Care Providers Index (the "underlying index"), which measures the performance of the healthcare providers sector of the U.S. equity market. The fund is non-diversified.

iShares US Medical Devices ( NYSEArca: IHI ) The investment seeks to track the investment results of an index composed of U.S. equities in the medical devices sector. The fund seeks to track the investment results of the Dow Jones U.S. Select Medical Equipment Index (the "underlying index"), which measures the performance of the medical equipment sector of the U.S. equity market. The underlying index includes medical equipment companies such as manufacturers and distributors of medical devices such as magnetic resonance imaging (MRI) scanners, prosthetics, pacemakers, X-ray machines, and other non-disposable medical devices. The fund is non-diversified.

iShares Nasdaq Biotechnology ( NasdaqGIDS IBB ) The investment seeks to track the investment results of an index composed of biotechnology and pharmaceutical equities listed on the NASDAQ. The fund generally invests at least 90% of its assets in securities of the underlying index and in depositary receipts representing securities of the underlying index. The underlying index contains securities of NASDAQ® listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals and that also meet other eligibility criteria determined by the NASDAQ OMX Group, Inc. The fund is non-diversified.

Market Vectors Biotech ETF ( NYSE MKT:BBH ) seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the Market Vectors® US Listed Biotech 25 Index. The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The Biotech Index is comprised of common stocks and depositary receipts of U.S. exchange-listed companies in the biotechnology sector. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. It is non-diversified.

PowerShares Dynamic Biotech & Genome ETF ( NYSEArca: PBE ) The investment seeks investment results that generally correspond (before fees and expenses) to the price and yield of the Dynamic Biotechnology & Genome IntellidexSM Index. The fund generally will invest at least 90% of its total assets in common stocks of biotechnology companies and genome companies that comprise the underlying intellidex. The underlying intellidex was composed of common stocks of 30 U.S. biotechnology and genome companies. These companies are engaged principally in the research, development, manufacture and marketing and distribution of various biotechnological products, services and processes, etc. It is non-diversified.

Related Guest Posts

Buy a guest post on Investorideas.com

Biotech News from Newsfile

PharmaDrug Signs Supply Agreement with European Cannabis Extractor for Medical Grade THC Oil to Be Sold Under PharmaDrug Brand
Toronto, Ontario--(Newsfile Corp. - May 14, 2021) - PharmaDrug Inc. (CSE: BUZZ) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company") a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, is pleased to announce that it has entered into a supply agreement (the "Supply Agreement") with an emerging Eurozone cannabis extractor for medical grade THC oil to be sold under PharmaDrug's own...

Universal PropTech Inc. Announces Insider Open-Market Stock Purchase
Toronto, Ontario--(Newsfile Corp. - May 14, 2021) - Universal PropTech Inc. (TSXV: UPI) (OTCQB: UPIPF) (FSE: 8LH) ("UPI" or the "Company") today announced that Christopher Hazelton, Chief Executive Officer of UPI, executed an open market stock purchase for 440,000 common shares of the Company through the facilities of the TSX Venture Exchange ("TSXV") on May 13, 2021, valued at approximately $115,000.Christopher Hazelton, CEO of the Company commented: "Given the recent milestones that Universal PropTech...

Entheon Biomedical Corp. Provides Corporate Update
Launch of Psychedelics DNA Test KitPhase 1 clinical trial for DMT progressing as plannedPre-clinical In Vivo work scheduled to start at Israeli CROStrengthened expertise focused on driving initiatives forwardUpgraded OTC Listing Financial UpdateVancouver, British Columbia--(Newsfile Corp. - May 14, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (FSE: 1XU1) (OTCQB: ENTBF) ("Entheon" or the "Company"), a biotechnology company focused on developing psychedelic medicines to treat addiction, is pleased to provide a corporate update on its operations...

American Aires Announces Private Placement
Toronto, Ontario--(Newsfile Corp. - May 13, 2021) - American Aires Inc. (CSE: WIFI) (the "Company" or "Aires") is pleased to announce that it intends to complete a non-brokered private placement (the "Private Placement") for gross proceeds of up to $5,000,000 through the issuance of up to 33,333,333 units (the "Units") at a price of $0.15 per Unit. Each Unit is comprised of one (1) common share in the capital of the Company ("Common Share") and...

Annovis Bio Files for FDA Orphan Drug Designation for ANVS401 for the Treatment of Alzheimer's Disease in Persons with Down Syndrome
Berwyn, Pennsylvania--(Newsfile Corp. - May 13, 2021) - Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, today announced it has filed an application with the U.S. Food and Drug Administration (FDA) to receive orphan drug designation for its lead drug candidate, ANVS401, for the treatment of AD in persons with Down syndrome (DS), referred to as DS-AD.DS occurs in about 1...

Subscribe to Biotech News